New progress in research on respiratory syncytial virus inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 597-610, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-820858
ABSTRACT
Respiratory syncytial virus (RSV) is the main pathogen causing respiratory infections in infants, the elderly, and immunocompromised individuals. Currently, ribavirin and the humanized monoclonal antibody palivizumab are commonly used for lower respiratory tract infections caused by RSV. However, their clinical application has been limited by their efficacy, economy and safety. Therefore, it is necessary to develop new RSV inhibitors to meet the needs of clinical prevention and treatment. This paper selects typical research cases and reviews the research progress of different target inhibitors from the perspective of medicinal chemistry.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS